UK MPs discuss tobacco control plan in Parliament

Dec.04.2022
UK MPs discuss tobacco control plan in Parliament
British MPs discuss using tobacco and alcohol taxes to reduce harm, with a new tobacco control plan to be released.

Rachael Maskell, a Labour representative from York, asked the Chancellor whether he intends to utilize the alcohol and tobacco tax in order to support plans aimed at reducing the harms caused by these products.


In response to the Prime Minister, James Cartlidge of South Suffolk County in the United Kingdom stated, "The government is constantly reviewing tax rates during the annual budget process with the aim of balancing the impact on businesses with its public health objectives.


Justice Secretary Alex Cunningham has called for the release of a new tobacco control plan in response to the autumn statement.


Stoke North MP is the Deputy Chairman of the All-Party Parliamentary Group on Smoking and Health. He has been criticized for the government's "lack of action in addressing health inequality issues.


He also wants to know why the government is not taxing the tobacco industry to provide funding for the long-delayed tobacco control plan.


Andrew Lewer, a representative from the southern part of Northampton, has questioned the Secretary of State for Health and Social Care about whether the data on adult smoking habits in the National Statistics Office report will be used to inform tobacco control plans.


Neil O'Brien, the Minister for Primary Care and Public Health, stated that the government is considering independent recommendations from the Khan Review and an updated tobacco control plan to determine the most appropriate response. O'Brien added that the plan, if released, will take into account the latest information from the Office for National Statistics on smoking habits among UK adults.


Peter Dowd asked the Secretary of State whether he would release data on the UK's progress towards achieving its adult smoking targets as planned.


Neil O'Brien responded by stating that the UK government set a target as part of the 2017 Tobacco Control Plan to reduce the adult smoking rate to 12% or lower by the end of 2022. The smoking rate was 19.8% in 2011 and 13.9% in 2019. Due to the COVID-19 pandemic, data for 2020 cannot be compared to previous years. However, based on the trend from 2019, it is expected that the target for 2022 will be achieved.


The smoking prevalence data for the year 2022 in the United Kingdom is set to be published in the "Adult Smoking Habits in the UK" publication by the National Statistics Office in 2023.


The House of Lords in the UK has received verbal questions regarding the tobacco control plan. Lord Faulkner of Worcester, Vice Chairman of the All-Party Parliamentary Group on Smoking and Health, asked the government when they plan to release the tobacco control plan, and if England still intends to achieve a smoke-free status by 2030.


The Deputy Secretary of State for Health and Social Welfare, Lord Markham, reiterated the government's commitment to the 2030 targets.


Finally, Bob Blackman, the Conservative MP for Harrow East and Chair of the All-Party Parliamentary Group on Smoking and Health, wrote an article about tobacco control issues in the political magazine Parliament.


2FIRSTS will continue to report on this topic, with further updates available on the '2FIRSTS APP.' Scan the QR code below to download the app.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
FDA Authorizes 24 VELO Nicotine Pouches, Increasing U.S. Authorized Total by 56%
The U.S. FDA authorized 24 VELO nicotine pouch products from a British American Tobacco subsidiary, raising the total number of authorized products from 43 to 67, a 55.8% increase. The newly authorized 4 mg products include lime and passion fruit flavors and feature certified child-resistant packaging. VELO's first FDA marketing authorization adds BAT to a list previously limited to PMI and Altria products, while bringing the agency's nicotine pouch review pilot total to 47 authorized products.
Oct.30
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Product | JT to Launch MEVIUS Tropical Option in Japan, Expanding Ploom Tobacco Stick Lineup to 32
Japan Tobacco (JT) will launch MEVIUS Tropical Option, a new tobacco stick for Ploom, nationwide in Japan from October 6, 2026. The capsule-format product combines mango-oriented sweetness with menthol cooling, adding a tropical flavor to the MEVIUS Ploom tobacco-stick lineup for the first time. Each pack contains 20 sticks and will launch at JPY 590. The product is compatible with all Ploom devices, and its addition will expand the Ploom tobacco-stick portfolio to 32 variants.
Sep.08
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
From Vuse, Velo and glo to AI Consulting: Former BAT Content Lead Launches Destreza
Former BAT global content lead Andy Parton has left the company and launched Destreza, a London-based AI-native marketing consultancy. Parton previously worked across BAT's New Category brands Vuse, Velo and glo and had also served as Global Brand Lead for Vuse Go. Destreza says it will advise consumer businesses on AI in brand strategy, operating models, capability and agency configuration, using specialist AI agents to support research, strategy and creative development. BAT reported £3.621 billion in New Category revenue in 2025.
Sep.22
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Philip Morris International (PMI) introduced TEREA Bold Red and Bold Black heated tobacco sticks in Germany in October 2026, both carrying a brand-rated tobacco-flavor intensity of 10, the highest level in the country's TEREA portfolio. Bold Red features leather and warm woody notes, while Bold Black combines woody and subtle floral notes. Both are sold in 20-stick packs at €8, approximately 2.6% above standard TEREA products. Germany's TEREA range now includes 11 flavor variants, alongside a separate 26-stick XL format priced at €10. IQOS Germany announced the new products on October 12, followed by a phased retail rollout from late October and an IQOS Club campaign running through December.
product
Nov.02
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08